Dr. Leila Alland
Equibles does not estimate personal net worth.
Get an email with a short summary when Cardiff Oncology, Inc. publishes a filing, an earnings call transcript or a press release.
Get CRDF alertsAbout Dr. Leila Alland
Cardiff Oncology, Inc. reported in an 8-K filed October 27, 2026 that Dr. Leila Alland was appointed interim Chief Medical Officer, effective October 23, 2026. Cardiff Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cardiff Oncology, Inc. includes Mani Mohindru (CEO), Mani Mohindru, Ph.D. (CEO), Mark Erlander (CEO) and 7 others.
“On October 23, 2026, the Company entered into an amended and restated consulting agreement with Leila Alland Md Consultancy LLC (the “Agreement”) pursuant to which Dr. Leila Alland will serve as interim Chief Medical Officer of the Company.”
Affiliation history
-
Cardiff Oncology, Inc. (CRDF)
SEC 8-K
Current2026-10-23–present
Company network
Leadership on record at Cardiff Oncology, Inc.
- Mani Mohindru CEO
- Mani Mohindru, Ph.D. CEO
- Mark Erlander CEO
- Mark Erlander, Ph.D. CEO
- Thomas H. Adams CEO
- Rodney Markin, M.D. Chairman
- James Levine CFO
- Josh Muntner CFO
- Joshua Muntner CFO
- Ajay Aggarwal, MD, MBA COO